Immix Biopharma, Inc. (IMMX)
IMMX Stock Price Chart
Explore Immix Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze IMMX price movements and trends.
IMMX Company Profile
Discover essential business fundamentals and corporate details for Immix Biopharma, Inc. (IMMX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 2021
Employees
18.00
Website
https://www.immixbio.comCEO
Ilya Rachman MBA,
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
IMMX Financial Timeline
Browse a chronological timeline of Immix Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.16.
Earnings released on 8 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.21 by -4.76%.
Earnings released on 8 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.23 by +34.78%.
Earnings released on 24 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.25 by +36.00%, while revenue for the quarter reached $96.29K .
Earnings released on 12 Nov 2024
EPS came in at -$0.24 falling short of the estimated -$0.16 by -50.00%.
Earnings released on 12 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%.
Earnings released on 9 May 2024
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%.
Earnings released on 29 Mar 2024
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.35%, while revenue for the quarter reached $4.78K .
Earnings released on 9 Nov 2023
EPS came in at -$0.23 matching the estimated -$0.23.
Earnings released on 11 Aug 2023
EPS came in at -$0.24 falling short of the estimated -$0.17 by -41.18%.
Earnings released on 12 May 2023
EPS came in at -$0.18 falling short of the estimated -$0.14 by -28.57%.
Earnings released on 27 Mar 2023
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%, while revenue for the quarter reached -$89.52M .
Earnings released on 9 Nov 2022
EPS came in at -$0.11 .
Earnings released on 12 Aug 2022
EPS came in at -$0.11 .
Earnings released on 13 May 2022
EPS came in at -$0.10 .
Earnings released on 28 Mar 2022
EPS came in at -$3.00 .
Earnings released on 30 Sept 2021
EPS came in at -$0.06 .
Earnings released on 30 Jun 2021
EPS came in at -$0.02 .
Earnings released on 31 Mar 2021
EPS came in at -$0.12 .
Earnings released on 31 Dec 2020
EPS came in at -$0.10 .
Earnings released on 30 Sept 2020
EPS came in at -$0.02 .
IMMX Stock Performance
Access detailed IMMX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.